RVL Pharmaceuticals plc Finite-Lived Intangible Asset, Expected Amortization, Year Three
RVL Pharmaceuticals plc had Finite-Lived Intangible Asset, Expected Amortization, Year Three of $2.79 million as of 2021-03-31, per its 10-Q filed 2021-05-13.
Discontinued › Notes › Goodwill and Other › Intangible Asset, Finite-Lived, and Capitalized Cost, Software to be Sold, Leased, or Marketed, Estimated Amortization Expense › Intangible Asset, Finite-Lived, after Accumulated Amortization, Estimated Amortization Expense, Fiscal Year Maturity
us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree · last filed 2021-05-13
- 2021-03-31: Finite-Lived Intangible Asset, Expected Amortization, Year Three $2.79M.
- 2020-12-31: Finite-Lived Intangible Asset, Expected Amortization, Year Three $4.74M.
- 2020-09-30: Finite-Lived Intangible Asset, Expected Amortization, Year Three $6.72M.
- 2020-06-30: Finite-Lived Intangible Asset, Expected Amortization, Year Three $11.16M.
| Period end | Finite-Lived Intangible Asset, Expected Amortization, Year Three |
|---|---|
| 2021-03-31 | $2.79M 10-Q · filed 2021-05-13 |
| 2020-12-31 | $4.74M 10-K · filed 2021-03-30 |
| 2020-09-30 | $6.72M 10-Q · filed 2020-11-10 |
| 2020-06-30 | $11.16M 10-Q · filed 2020-08-11 |
| 2020-03-31 | $12.69M 10-Q · filed 2020-05-12 |
| 2019-12-31 | $12.69M 10-K · filed 2020-03-19 |
| 2019-09-30 | $19.84M 10-Q · filed 2019-11-14 |
| 2019-06-30 | $44.89M 10-Q · filed 2019-08-08 |
| 2019-03-31 | $58.18M 10-Q · filed 2019-05-09 |
| 2018-12-31 | $65.35M 8-K · filed 2019-12-20 |
| 2018-09-30 | $68.32M 10-Q · filed 2018-11-08 |